The U.S. Patent and Trademark Office has approved a patent for the use of eriocitrin in Ingredient By Nature’s ingredient formulations, such as Eriomin, a citrus flavonoid designed for blood glucose support.
Photo © iStockphoto.com/eli_asenova
The U.S. Patent and Trademark Office has approved a patent for the use of eriocitrin in Ingredient By Nature’s (IBN; Montclair, CA) ingredient formulations, such as Eriomin, a citrus flavonoid designed for blood glucose support. The specific patent claim states that eriocitrin can be used as, “A method of reducing blood glucose levels in a human subject in need thereof, comprising administering to the subject a composition comprising 100-200 mg eriocitrin once per day.”
“We couldn’t be happier with the progress we have made to recognize eriocitrin as a viable option for better health,” said Rob Brewster, president of IBN, in a press release. “Supported by a successful first clinical trial and now this patent, our line of Eriomin lemon flavonoid blends, which are primarily comprised of eriocitrin, provide powerful support to managing healthy blood glucose levels. We look forward to revealing additional significant results from ongoing research into the effect that eriocitrin can have on blood glucose levels later this year.”
What's next for NPA and CRN in their complaints against New York state?
May 2nd 2024The latest updates in the efforts of the Natural Products Association and the Council for Responsible Nutrition to sue New York state for its law banning the sale of weight management and muscle building supplements to minors.
Judge denies CRN’s motion for preliminary injunction but its lawsuit against NY state will proceed
April 23rd 2024The judge in CRN's lawsuit against NY state's law banning the sale of weight management and muscle building supplements to minors has denied its motion for a preliminary injunction, but determined that CRN has standing to sue on behalf of its members.